Literature DB >> 24431345

Reply to Ki67 in breast cancer: a useful prognostic marker!

C Denkert1, G von Minckwitz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24431345     DOI： 10.1093/annonc/mdt564

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  7 in total

1.  Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

Authors:  A S Coates; E P Winer; A Goldhirsch; R D Gelber; M Gnant; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2015-05-04       Impact factor: 32.976

2.  Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients.

Authors:  Li Ding; Zijin Zhang; Yan Xu; Yongqiang Zhang
Journal:  Bioengineered       Date:  2017-01-11       Impact factor: 3.269

3.  Prognostic implications of regression of metastatic axillary lymph nodes after neoadjuvant chemotherapy in patients with breast cancer.

Authors:  Yul Ri Chung; Ji Won Woo; Soomin Ahn; Eunyoung Kang; Eun-Kyu Kim; Mijung Jang; Sun Mi Kim; Se Hyun Kim; Jee Hyun Kim; So Yeon Park
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.379

4.  Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up.

Authors:  Sara Bustreo; Simona Osella-Abate; Paola Cassoni; Michela Donadio; Mario Airoldi; Fulvia Pedani; Mauro Papotti; Anna Sapino; Isabella Castellano
Journal:  Breast Cancer Res Treat       Date:  2016-05-07       Impact factor: 4.872

5.  Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study.

Authors:  André Hennigs; Fabian Riedel; Adam Gondos; Peter Sinn; Peter Schirmacher; Frederik Marmé; Dirk Jäger; Hans-Ulrich Kauczor; Anne Stieber; Katja Lindel; Jürgen Debus; Michael Golatta; Florian Schütz; Christof Sohn; Jörg Heil; Andreas Schneeweiss
Journal:  BMC Cancer       Date:  2016-09-15       Impact factor: 4.430

6.  Prognostic significance of Ki67 in Chinese women diagnosed with ER+/HER2- breast cancers by the 2015 St. Gallen consensus classification.

Authors:  Yue Hu; Ran Gu; Jinghua Zhao; Yaping Yang; Fengtao Liu; Liang Jin; Kai Chen; Haixia Jia; Hongli Wang; Qiang Liu; Fengxi Su; Weijuan Jia
Journal:  BMC Cancer       Date:  2017-01-06       Impact factor: 4.430

7.  The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2.

Authors:  Tarek M A Abdel-Fatah; Robert C Rees; A Graham Pockley; Paul Moseley; Graham R Ball; Stephen Y T Chan; Ian O Ellis; Amanda K Miles
Journal:  Oncotarget       Date:  2017-11-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.